Jordan Spencer
Psychiatry · Charleston, SCNPI 1851886782
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,025 of the $61,885 with a category attached, or 79.2%. Axsome Therapeutics, Inc. accounts for 82.9% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $57,966, more than ten times the $103 reported in 2019. Among psychiatry clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 459 payments — averaging $134.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$51K
- Alkermes, Inc.$4K
- AbbVie$1K
- Vanda Pharmaceuticals Inc.$922
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$590
- Johnson & Johnson$407
- plus $3K from 22 others
What the payments were for
- Consulting fees$1,0002%
- Speaking & faculty fees$49,02579%
- Travel & lodging$3,4286%
- Food & beverage$8,42814%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 94 | $51,322 |
| Alkermes, Inc. | 34 | $4,151 |
| AbbVie | 85 | $1,325 |
| Vanda Pharmaceuticals Inc. | 37 | $922 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 31 | $590 |
| Johnson & Johnson | 19 | $407 |
| Lundbeck LLC | 22 | $377 |
| Otsuka America Pharmaceutical, Inc. | 19 | $363 |
| Neos Therapeutics, LP | 21 | $245 |
| Neurocrine Biosciences, Inc. | 10 | $239 |
| Janssen Scientific Affairs, LLC | 1 | $200 |
| Indivior Inc. | 9 | $175 |
| Bausch Health US, LLC | 8 | $172 |
| Harmony Biosciences LLC | 8 | $151 |
| Noven Therapeutics, LLC | 7 | $149 |
| Idorsia Pharmaceuticals US Inc | 7 | $149 |
| Teva Pharmaceuticals USA, Inc. | 8 | $145 |
| Corium, LLC | 6 | $122 |
| E.r. Squibb & Sons, L.L.C. | 5 | $110 |
| Tris Pharma Inc | 5 | $106 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $103 |
| Almatica Pharma LLC | 6 | $89 |
| Pfizer | 4 | $86 |
| Braeburn Inc. | 4 | $63 |
| Collegium Pharmaceutical, Inc. | 3 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Merck | 1 | $22 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$61,885 in reported general payments places this provider in the 95th percentile of 624 psychiatry providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 20 | $2,226 |
| Alprazolam | 12 | $362 |
| Duloxetine Hcl | 13 | $135 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 11 | $64 |
| Trazodone Hcl | 19 | $63 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Charleston
- Ricardo FermoCharleston$262K
- Jacobo MintzerCharleston$132K
- Floyd SalleeCharleston$121K
- Kathleen BradyCharleston$83K
- James BallengerCharleston$35K
- Mark HamnerCharleston$24K
- Constance AlexanderCharleston$20K
- Mark GeorgeCharleston$17K
- Lalithkumar SolaiCharleston$12K
- Michael WilcoxCharleston$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.